SomnoMed: Scaling Sleep-Apnea Treatment Through Clinical Alignment, Manufacturing Discipline and Better Digital Workflows
SomnoMed occupies a distinctive place in healthcare because it sits at the intersection of medical treatment, dental workflow and patient adherence. The company says it is the world’s largest supplier of oral sleep-apnea devices, operates in 28 countries and has now delivered more than one million oral appliances for obstructive sleep apnea. That scale gives it a very different profile from a small niche medtech supplier: it is already a global operating platform in a therapy category that continues to gain wider clinical acceptance.
FY25 was a major year for the company financially. In its annual report, SomnoMed said it generated revenue of $111.5 million, up 21.6% on FY24, returned to positive EBITDA of $9.2 million, and delivered positive free cash flow of $0.8 million. The same report described FY25 as exceptional and noted that SomnoMed became the first oral-appliance company in the world to have treated more than one million patients to date.
Those numbers matter because they suggest the business is moving beyond recovery and into a more scalable operating phase. SomnoMed’s FY25 materials also said the operational improvement program launched in FY24 continued to deliver strong results in FY25, with increased production capacity, process optimisation, improved turnaround times and order backlog reduced to negligible levels. In a custom-manufactured medical-device business, those are not minor process wins — they are central to growth and customer confidence.
The strongest part of the SomnoMed story, though, is how clearly the company’s partner ecosystem is defined. Its public materials repeatedly position SomnoMed as working in concert with dental sleep professionals and sleep physicians, rather than trying to bypass either side of the care pathway. The company says dentists and sleep physicians work together to diagnose and identify the most effective treatment for each patient, and that its milestone of more than one million devices reflects the role of both dental practitioners and physician collaborators.
That collaborative treatment model is one reason the company feels more embedded than many device makers. SomnoMed is not just shipping appliances into clinics; it is supporting a workflow in which physicians diagnose and oversee care, dentists fit and monitor appliances, and the patient is managed through a more integrated oral-appliance therapy pathway. That is exactly the kind of clinical alignment that can help broaden adoption in a treatment category still often compared against CPAP.
Its product suite is also becoming more digitally enabled. On its SomnoDent Avant pages, the company says the device is designed from a digital photo or scan of the patient’s teeth using CAD tools and then milled by computer-controlled robots. SomnoMed has also explicitly promoted digital scanning with the iTero intraoral scanner, describing it as a workflow enhancer for dental sleep medicine and broader practice efficiency.
That link with iTero is especially relevant because it gives the company a tangible technology-partner angle. Digital scanning is not simply a convenience feature here; it supports SomnoMed’s “First Time Fit” proposition, reduces chair time, and helps standardise the front end of a highly customised manufacturing process. In a business built around patient comfort and long-term compliance, getting the fit right quickly is commercially and clinically meaningful.
The patient-use data SomnoMed publishes helps reinforce that point. On its physician-facing materials, the company says SomnoDent Avant users average 6.9 hours of nightly use and that 91% report improved sleep quality. Those figures are not a substitute for broader clinical literature, but they are useful as a reflection of how SomnoMed wants the market to understand its core value proposition: not just efficacy on paper, but real-world adherence.
There is also a commercial-education layer to how the company is scaling. SomnoMed says it restructured its North American business to include dedicated field-based business development representatives focused on medical education, with separate account management and customer-service teams supporting sleep dentists. That kind of organisational change signals a business trying to grow not only by improving manufacturing, but also by widening professional acceptance and referral quality.
The challenge section is best framed around category adoption rather than company-specific distress. Oral appliance therapy continues to compete for clinical attention alongside CPAP, and in many markets the referral pathway still needs to be built more deliberately. SomnoMed’s response has been to invest in medical education, physician relationships, dentist support and digital workflow improvements, rather than simply pushing product volume.
There is a longer history behind the product as well. SomnoMed notes that SomnoDent was based on the original invention of Dr. Richard Palmisano, and that the product family has evolved through continuous improvement and scientifically validated development. That helps the company’s profile because it gives the business a clinical-origin story rather than a purely commercial one.
What makes SomnoMed a strong feature is that its collaborators are essential to its success. Sleep physicians, dental sleep medicine practitioners and technology partners like iTero all shape how the product is prescribed, fitted and supported. Combined with the company’s stronger FY25 performance and improved operational execution, that ecosystem suggests SomnoMed is building scale in a way that feels grounded, clinically aligned and increasingly repeatable.
